Azitra, Inc. (AZTR)

NYSEAMERICAN: AZTR · IEX Real-Time Price · USD
0.175
-0.007 (-4.00%)
At close: Apr 12, 2024, 4:00 PM
0.185
+0.010 (5.59%)
Pre-market: Apr 15, 2024, 4:04 AM EDT
-4.00%
Market Cap 5.05M
Revenue (ttm) 686,000
Net Income (ttm) -12.64M
Shares Out 28.80M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 300,266
Open 0.183
Previous Close 0.183
Day's Range 0.170 - 0.185
52-Week Range 0.161 - 5.180
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 6, 2024

About AZTR

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggri... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2023
Employees 10
Stock Exchange NYSEAMERICAN
Ticker Symbol AZTR
Full Company Profile

Financial Performance

In 2023, Azitra's revenue was $686,000, an increase of 141.55% compared to the previous year's $284,000. Losses were -$12.64 million, -6.02% less than in 2022.

Financial Statements

News

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...

4 weeks ago - Business Wire

Azitra, Inc. Announces Closing of Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, t...

2 months ago - Business Wire

Azitra, Inc. Announces Pricing of Public Offering

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...

2 months ago - Business Wire

Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

3 months ago - Business Wire

Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced t...

3 months ago - Business Wire

Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported fi...

5 months ago - Business Wire

Azitra to Present at the ThinkEquity Conference

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today t...

6 months ago - Business Wire

Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRANFORD, Conn., Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, anno...

8 months ago - PRNewsWire

Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates

BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

8 months ago - PRNewsWire

Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors

BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

9 months ago - PRNewsWire

Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

9 months ago - PRNewsWire

Azitra, Inc. Announces Closing of Initial Public Offering

BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...

10 months ago - PRNewsWire

Azitra, Inc. Announces Pricing of Initial Public Offering

BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology usi...

10 months ago - PRNewsWire